LSX Nordic Congress

✨ The LSX Nordic Congress is heading to Bergen We’re thrilled to announce that the LSX Nordic Congress is moving to Bergen, Norway next year! Mark your calendar for 20th - 21st May 2025, as we bring our gathering of life science leaders in Northern Europe to a new setting.   Why Norway? As a hub for life sciences, Norway offers a perfect blend of thriving innovation, global partnerships, and cutting-edge research – making it an ideal backdrop for the LSX Nordic Congress in 2025. Curious about who you’ll meet? - https://lnkd.in/eUnVXcnp Explore this year’s highlights for a snapshot of 2024’s attendee insights, from regional representation to industry expertise and seniority. You’ll also find a list of attending companies and a guide to investor interests and preferences.   Save Big by Planning Ahead! - https://lnkd.in/eRRJ88F2 Get ahead of the crowd and lock in your spot early – book by January 31 and save up to €650! Why wait? Secure your place now and make the most of this exclusive rate before prices go up. #LSXNordic #LifeScience #Biotech #Medtech #Healthtech #Investment #Partnership

Do we have gender equality in health? That was the main question for the panel discussion on Nordic perspectives on Women's Health at the LSX Nordic Congress. And the short answer is no - at least not yet. Ulrika Ringdahl from SmiLe Venture Hub pointed out that the Nordics are frontrunners in gender equality and should also be in Women's Health. We have all the possibilities but we need funding already at the research level. Sana Alajmovic from Sigrid Therapeutics advocated for bringing women into clinical studies earlier and to set up investment funds focusing on women's health. Ina Laura Perkins from Scandinavian Real Heart talked about the need to look at the products already on the market for female patients, as most of them has been developed for men initially. And Pernille Ravn Jakobsen from OSAIA Health had a wish that the politicians would stop talking and start doing. We need funding precisely allocated for specific women's health issues. Moderator Anette Steenberg could sum up that what we need is (still) earmarked funding and regulation. I take home a lot of fresh inspiration to the Medicon Valley Alliance Women's Health network. If you are interested in learning more about the network or joining one of our events, please reach out to me.

As the media partner we had a chat with Josh Dance from LSX - partnering for Life Science eXecutives about the LSX Nordic Congress, an important event that connects leaders in the life science and healthcare sectors with international investors and strategic partners. Josh shares insights into how the congress aims to drive growth, development, and internationalization of Nordic and Baltic life science and healthcare innovations.   Don’t miss this opportunity to learn more about the future of life sciences in the Nordic and Baltic regions! Watch the full interview here! #LSXConference2024

Thank you LSX - partnering for Life Science eXecutives for inviting me to discuss the hottest topic: when and how AI will impact life science. The take-home? When? - Now. All major pharma companies already have significant efforts in using AI to improve drug development. As Julie Klint shared nuances about, AI has proven itself useful in small molecule design, yielding sizable improvements in speed and quality. - Soon. There are several interesting readouts of AI-generated assets (depending on your definition of AI-generated) in the coming 18 months, which can validate some of the AI-powered biotechs, which so far have resulted in few approved assets. The proof is in the pudding. How? - Two main ways: generic capabilities (e.g. reading and summarizing scientific literature, meeting summaries, internal coordination) at first and specific ones (e.g. target identification, lead generation) after that. - All pharma companies require some in-house knowledge to navigate and manage the implementation of AI, but most will stay true to their existing core business and not become software companies. Thus the need for external innovators (e.g. recent partnership between Iambic Therapeutics and Lundbeck) - Challenges and uncertainties remain in big pharma, e.g. in organizing data to be useful to AI models, changing processes and ways of working. That's why the first processes to be improved by AI will be those with fewer interdependencies, which can relatively be automated/improved without having to change many things at once - It seems as though those who have come far, e.g. Genmab as Hisham explained, may reap over-sized benefits as the models become more powerful and capabilities and use cases expand. Thank you for a great discussion Julie Klint, Hisham Hamadeh, Paul Ainsworth, Daniel Schmidt! #lsx #ai #lifescience #venturecapital

Great to be part of opening the Nordic LSX - partnering for Life Science eXecutives life science conference. Thanks to Nasdaq for letting us open the market, and to Rachel Curtis Gravesen for great moderation of the opening panel. #lifescience #investing #nordic #innovation

Nasdaq Nordic markets opened at LSX - partnering for Life Science eXecutives event in Copenhagen. Great to be here with Carsten Borring and Peter Legind-Hansen representing our Nordic listing venues

I had the privilege of joining a dynamic panel debate on “The 2030 Vision: The Economic Potential and Future of Nordic Healthcare” at LSX - partnering for Life Science eXecutives LSX serves as a vital platform for innovators to connect with international investors and partners, driving the growth and global impact of Northern Europe's life sciences. During our discussion on enhancing sustainability in Nordic healthcare, we reached a consensus on several key points: 🎯 The importance of establishing clear public-private commitments focused on long-term, people-centered missions. 🔑 The need for improved access to both public and private data, fostering trust to stimulate innovation. 💵 The necessity for new incentives to adopt existing innovative solutions through risk-sharing procurement models and courageous leadership. 🆕 A call for greater emphasis on implementation skills across sectors, with strong health competencies as the cornerstone of a healthy population. A huge thank you to our incredible moderator Anette Steenberg and my insightful fellow panelists Bogi Eliasen Kenneth Forsstrøm Jensen Frederik Knud Nielsen and Troels Bierman Mortensen for the rich discussions and shared experience! Medicon Valley Alliance Roche Novartis Copenhagen Institute for Futures Studies DataFair. Danish Life Science Cluster

🌟 What an incredible Day 1 at the LSX Nordic Congress! 🌟 🤝 The energy and enthusiasm from all our attendees has been truly inspiring. 💬 Let’s keep the momentum going! Share your experiences, and be sure to use #LSXNordic to keep the conversation going! Looking forward to another fantastic day ahead with all of you!

Thrilled to moderate the closing keynote panel at the first day of our LSX Nordic Congress ! Navigating the ‘Nordic nexus’ of pharma deal-making and beyond, joined by Novo Nordisk’s Jane Buus Laursen, Lundbeck’s Keld Flintholm Jørgensen, and Astellas Pharma’s Nuno Alves, PhD 🧬 🤝🏼 Looking forward to tomorrow’s content featuring the current biotech IPO market, advanced therapies, women’s health innovation, and Nordic anti-microbial leadership #biotech #investment #pharma #copenhagen 🇩🇰